Overview

Thorough QT/QTc of Pritelivir in Healthy Subjects

Status:
Recruiting
Trial end date:
2023-05-18
Target enrollment:
Participant gender:
Summary
This Phase 1 clinical trial is a double-blind, single-center, randomized, placebo- and positive-controlled, parallel-group, 'nested crossover' trial with multiple oral dose administration of pritelivir or matching placebo as well as a single oral administration of moxifloxacin (positive control) and corresponding matching placebo in healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
AiCuris Anti-infective Cures AG
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Pritelivir